Company profile
NUCANA PLC
NASDAQ:NCNABiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FOSGEMCITABINE PALABENAMIDE | phase3 | — | 2 | terminated |
| FOSIFLOXURIDINE NAFALBENAMIDE | phase2 | — | 3 | completed, terminated |
| FOSDESDENOSINE SIPALABENAMIDE | phase1_2 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03829254 | phase1_2 | recruiting | 2019-06-17 | 2026-08-01 | NuCana plc | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma |
| NCT03428958 | phase1_2 | completed | 2018-10-05 | 2024-03-19 | NuCana plc | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment |
| NCT05678257 | phase2 | terminated | 2023-04-18 | 2024-08-29 | NuCana plc | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer |
| NCT04163900 | phase3 | terminated | 2019-12-24 | 2022-03-02 | NuCana plc | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer |
| NCT03146663 | phase2 | terminated | 2017-09-28 | 2019-12-31 | NuCana plc | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer |
FDA applications (0)
No records yet.